Orforglipron
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 600
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Orforglipron Dose 1 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Orforglipron Dose 2 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Orforglipron Dose 3 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Orforglipron Dose 4 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |